A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs

Choong Kim, Junichi Kasuya, Jessie Jeon, Seok Chung, Roger D. Kamm

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell culture-based drug screening models are increasingly employed. However, there is no in vitro high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions for the quantitative assessment of physiological responses to chemoattractant reagents under various concentrations of anti-angiogenesis drugs. Here we describe a method for screening and quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on human umbilical vein endothelial cells (HUVECs) cultured with different concentrations of bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death is preceded by a series of morphological changes that develop over several days. We also explore the mechanisms by which bortezomib can inhibit angiogenesis. This journal is

Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalLab on a Chip - Miniaturisation for Chemistry and Biology
Volume15
Issue number1
DOIs
Publication statusPublished - 2015 Jan 7

Fingerprint

Angiogenesis Inhibitors
Microfluidics
Screening
Endothelial cells
Tumors
Pharmaceutical Preparations
High-Throughput Screening Assays
Neoplasms
Preclinical Drug Evaluations
Proteasome Inhibitors
Chemotactic Factors
Human Umbilical Vein Endothelial Cells
Cell death
Cell culture
Vascular Endothelial Growth Factor A
Nutrients
Assays
Blood
Cell Death
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)
  • Bioengineering
  • Biomedical Engineering

Cite this

A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs. / Kim, Choong; Kasuya, Junichi; Jeon, Jessie; Chung, Seok; Kamm, Roger D.

In: Lab on a Chip - Miniaturisation for Chemistry and Biology, Vol. 15, No. 1, 07.01.2015, p. 301-310.

Research output: Contribution to journalArticle

@article{c100b0e70568438dbbfc1ff5d44a71e6,
title = "A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs",
abstract = "Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell culture-based drug screening models are increasingly employed. However, there is no in vitro high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions for the quantitative assessment of physiological responses to chemoattractant reagents under various concentrations of anti-angiogenesis drugs. Here we describe a method for screening and quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on human umbilical vein endothelial cells (HUVECs) cultured with different concentrations of bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death is preceded by a series of morphological changes that develop over several days. We also explore the mechanisms by which bortezomib can inhibit angiogenesis. This journal is",
author = "Choong Kim and Junichi Kasuya and Jessie Jeon and Seok Chung and Kamm, {Roger D.}",
year = "2015",
month = "1",
day = "7",
doi = "10.1039/c4lc00866a",
language = "English",
volume = "15",
pages = "301--310",
journal = "Lab on a Chip - Miniaturisation for Chemistry and Biology",
issn = "1473-0197",
publisher = "Royal Society of Chemistry",
number = "1",

}

TY - JOUR

T1 - A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs

AU - Kim, Choong

AU - Kasuya, Junichi

AU - Jeon, Jessie

AU - Chung, Seok

AU - Kamm, Roger D.

PY - 2015/1/7

Y1 - 2015/1/7

N2 - Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell culture-based drug screening models are increasingly employed. However, there is no in vitro high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions for the quantitative assessment of physiological responses to chemoattractant reagents under various concentrations of anti-angiogenesis drugs. Here we describe a method for screening and quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on human umbilical vein endothelial cells (HUVECs) cultured with different concentrations of bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death is preceded by a series of morphological changes that develop over several days. We also explore the mechanisms by which bortezomib can inhibit angiogenesis. This journal is

AB - Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell culture-based drug screening models are increasingly employed. However, there is no in vitro high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions for the quantitative assessment of physiological responses to chemoattractant reagents under various concentrations of anti-angiogenesis drugs. Here we describe a method for screening and quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on human umbilical vein endothelial cells (HUVECs) cultured with different concentrations of bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death is preceded by a series of morphological changes that develop over several days. We also explore the mechanisms by which bortezomib can inhibit angiogenesis. This journal is

UR - http://www.scopus.com/inward/record.url?scp=84915793469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915793469&partnerID=8YFLogxK

U2 - 10.1039/c4lc00866a

DO - 10.1039/c4lc00866a

M3 - Article

C2 - 25370780

AN - SCOPUS:84915793469

VL - 15

SP - 301

EP - 310

JO - Lab on a Chip - Miniaturisation for Chemistry and Biology

JF - Lab on a Chip - Miniaturisation for Chemistry and Biology

SN - 1473-0197

IS - 1

ER -